MILWAUKEE, Nov. 1, 2024
The Society for Immunotherapy of Cancer (SITC) received over 1,500 abstract submissions in 2024, and has announced titles and authors for 42 accepted Late-Breaking Abstracts (LBA). New for 2024, all of the Late-breaking Abstracts contain late-breaking data from interventional clinical trials in humans. The abstracts will be presented at SITC's upcoming 39th Annual Meeting & Pre-Conference Programs taking place November 6–10, 2024, in Houston, TX and virtually.
Advertisement
MILWAUKEE, Nov. 1, 2024 /PRNewswire-PRWeb/ -- The Society for Immunotherapy of Cancer (SITC) received over 1,500 abstract submissions in 2024, and has announced titles and authors for 42 accepted Late-Breaking Abstracts (LBA). New for 2024, all of the Late-breaking Abstracts contain late-breaking data from interventional clinical trials in humans. The abstracts will be presented at SITC's upcoming 39th Annual Meeting & Pre-Conference Programs taking place November 6–10, 2024, in Houston, TX and virtually.
Advertisement
SITC also invites you to attend the virtual press briefing of the society's 39th Annual Meeting (SITC 2024) beginning at 12:00 p.m. CT on Wednesday, Nov. 6, 2024.
The abstracts selected for the press briefing represent an array of the top advances in cancer immunotherapy research. Data shared during the press briefing may be embargoed to a later date and time during the Annual Meeting and that information will be shared during the presentation. For more information, please review the SITC 2024 Media Policy.
The schedule of presentations and press briefing presenters are listed in order below:
Abstract #463: Antigen-responsive promoters coupled with cytoDRiVE® technology provide tight spatiotemporal regulation for tumor-infiltrating lymphocytes (TIL) expressing membrane-bound IL12 Presenter: Sean Smith, MD & Jan ter Meulen, MD, PhD - Obsidian Therapeutics
Abstract #687: ACTengine IMA203 TCR-T targeting PRAME shows deep and durable anti-tumor activity in heavily pretreated solid cancer patients Presenter: Martin Wermke, MD - TU Dresden
Abstract #591: In-situ vaccination by Tumor Treating Fields and anti-PD-1 immunotherapy in patients with large residual GBM results in robust T cell selection and expansion, high response rate, and extended survival Presenter: David Tran, MD, PhD - University of Southern California
Abstract #991: ST101, an inhibitor of the transcription factor C/EBPß, promotes an immune-active tumor microenvironment in a window of opportunity (WoO) study of patients with glioblastoma (GBM) Presenter: Jim Rotolo, PhD - Sapience Therapeutics
Abstract #1502: Efficacy and safety results of first-in-class PD-1/IL-2a-bias bispecific antibody fusion protein IBI363 in patients with immunotherapy-naïve advanced melanoma Presenter: Bin Lian - Peking University Cancer Hospital & Institute
Abstract #620: HBI-8000, a class I histone deacetylase (HDAC) inhibitor, in combination with nivolumab for treatment of anti-PD(L)1-naive advanced melanoma: final analysis of Study HBI-8000-302 Presenter: Nikhil Khushalani, MD - Moffitt Cancer Center
Abstract #756: A phase 2 trial of the IO102-IO103 cancer vaccine plus pembrolizumab: results from the first-line (1L) cohort of PD-L1 high metastatic non-small cell lung cancer (NSCLC) Presenter: Jonathan Riess, MD, MS - UC Davis Cancer Center
Abstract #1470: START001: A Phase 1/2 study of Invikafusp alfa (STAR0602), a first-in-class TCR ß chain-targeted bispecific antibody, as monotherapy in patients with antigen-rich solid tumors resistant to anti-PD(L)1 Presenter: James Gulley, MD, PhD - National Cancer Institute
ADDITIONAL DETAILS: Participating members of the media will have the opportunity to submit questions for up to three minutes following each presentation. To attend this press briefing, you must register as a member of the press for SITC 2024. To register, please visit https://www.sitcancer.org/2024/press/press-registration.
After registration is confirmed, you will receive instructions for the briefing. For more information regarding SITC 2024, please visit the Annual Meeting website at http://www.sitcancer.org/2024.
About SITC Established in 1984, the Society for Immunotherapy of Cancer (SITC) is a nonprofit organization of medical professionals dedicated to improving cancer patient outcomes by advancing the development, science and application of cancer immunotherapy and tumor immunology. SITC is comprised of influential basic and translational scientists, practitioners, health care professionals, government leaders and industry professionals around the globe. Through educational initiatives that foster scientific exchange and collaboration among leaders in the field, SITC aims to one day make the word "cure" a reality for cancer patients everywhere. Learn more about SITC, our educational offerings and other resources at sitcancer.org and follow us on X, LinkedIn, and YouTube.
Media Contact
Thomas Martin, Society for Immunotherapy of Cancer, 414-271-2456, [email protected], www.sitcancer.org
View original content to download multimedia:https://www.prweb.com/releases/the-society-for-immunotherapy-of-cancer-announces-late-breaking-abstracts-and-press-briefing-presented-at-39th-annual-meeting-302293831.html
SOURCE Society for Immunotherapy of Cancer
